Dr Shelley Boyd
Dr. Boyd is a Scientist and Ophthalmologist specializing in diseases of the retina, and is Director of Canada's first and only High Risk Dry AMD clinic at St. Michael's Hospital. She brings a strong pharmaceutical perspective to her work, having headed the global research program for Novartis Pharmaceuticals that brought treatments for wet AMD to the forefront. As an entrepreneur, Dr. Boyd alongside St. Michael's Hospital, spun out two biotech companies, Translatum Medicus inc (TMi) and Tracery Ophthalmics inc, both housed with JLABS@Toronto, within the MaRS Discovery District. Leveraging her knowledge of the pharmaceutical industry, along with science and medicine, Dr. Boyd is highly focused on moving a treatment for dry AMD from the lab to the clinic.